Covalon Technologies Ltd.

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, perioperative dressings, silicone dressings, vascular access line guards, and wound dressings; and surgical, peri-operative, and infection management products. It sells its products directly and through independent distributors under the ColActive, ColActive PLUS, CovaWound, CovaView, CovaClear IV, IV Clear, SurgiClear, MediClear, and VALGuard brands. The company serves health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.